Results 21 to 30 of about 924,854 (308)

Chimeric Antigen Receptor T-Cell Therapy [PDF]

Journal of the National Comprehensive Cancer Network, 2018
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases.
Ndiya, Ogba, Nicole M, Arwood, Nancy L, Bartlett, Mara, Bloom, Patrick, Brown, Christine, Brown, Elizabeth Lihua, Budde, Robert, Carlson, Stephanie, Farnia, Terry J, Fry, Morgan, Garber, Rebecca A, Gardner, Lauren, Gurschick, Patricia, Kropf, Jeff J, Reitan, Craig, Sauter, Bijal, Shah, Elizabeth J, Shpall, Steven T, Rosen   +18 more
openaire   +2 more sources

Chimeric Antigen Receptors for T-Cell Malignancies

Frontiers in Oncology, 2019
Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed
Lauren D. Scherer, Lauren D. Scherer, Malcolm K. Brenner, Malcolm K. Brenner, Malcolm K. Brenner, Maksim Mamonkin, Maksim Mamonkin, Maksim Mamonkin, Maksim Mamonkin   +8 more
doaj   +1 more source

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]

, 2012
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
A Lundqvist, A Somers, C Berger, CA Tran, Carolina Berger, Cornelis JM Melief, Daniel J Powell, David F Stroncek, DG Song, DJ Powell Jr, DL Porter, Francesco M Marincola, G Mostoslavsky, GG Kenter, Gustavo Mostoslavsky, J Jin, J Staerk, James R Heath, Jeffrey S Miller, JN Kochenderfer, JN Kochenderfer, John O'Shea, JS Miller, K Takahashi, L Gattinoni, L Gattinoni, L Gattinoni, L Gattinoni, LA Johnson, Luca Gattinoni, M Kalos, M Kalos, M Kalos, Mahendra Rao, Mark E Dudley, Martin A Cheever, ME Dudley, ME Dudley, Michael Kalos, Nicholas P Restifo, P Muranski, Peter Flynn, PF Robbins, RA Morgan, Richard W Childs, SA Rosenberg, Steven A Rosenberg, TS Park, X Wang   +48 more
core   +4 more sources

The second touch hypothesis: T cell activation, homing and polarization [v1; ref status: indexed, http://f1000r.es/2w7]

F1000Research, 2014
The second touch hypothesis states that T cell activation, proliferation, induction of homing receptors and polarization are distinguishable and, at least in part, sequential. The second touch hypothesis maintains that full T cell polarization requires T
Klaus Ley
doaj   +1 more source

The second touch hypothesis: T cell activation, homing and polarization [v2; ref status: indexed, http://f1000r.es/3zq]

F1000Research, 2014
The second touch hypothesis states that T cell activation, proliferation, induction of homing receptors and polarization are distinguishable and, at least in part, sequential. The second touch hypothesis maintains that full T cell polarization requires T
Klaus Ley
doaj   +1 more source

Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production [PDF]

, 2016
Self-tolerance and immunity are actively acquired in parallel through a poorly understood ability of antigen receptors to switch between signaling death or proliferation of antigenbinding lymphocytes in different contexts.
Domaschenz, Heather, Fung, Herman, Goodnow, Christopher, Horikawa, Keisuke, Jeelall, Yogeshraj, Kallies, Axel, Law, Hsei-Di, Nutt, Stephen L, Wang, James   +8 more
core   +1 more source

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Nature Communications, 2022
Antigen escape represents a potential drawback of chimeric antigen receptor T cell (CAR-T) therapy targeting a single tumor-associated antigen. To reduce the risk of antigen escape, here the authors report the design and characterization of a BAFF ligand
Derek P. Wong, Nand K. Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey-Son, Samantha Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Paolo Caimi, Reshmi Parameswaran   +12 more
doaj   +1 more source

Tracking global changes induced in the CD4 T-cell receptor repertoire by immunization with a complex antigen using short stretches of CDR3 protein sequence. [PDF]

, 2014
The clonal theory of adaptive immunity proposes that immunological responses are encoded by increases in the frequency of lymphocytes carrying antigen-specific receptors. In this study, we measure the frequency of different T-cell receptors (TcR) in CD4 +
Best, K, Chain, B, Cinelli, M, Friedman, N, Gal, H, Madi, A, Reich-Zeliger, S, Shawe-Taylor, J, Shifrut, E, Thomas, N   +9 more
core   +1 more source

Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells

EBioMedicine, 2016
Dendritic cells (DCs) are major antigen-presenting cells that can efficiently prime and cross-prime antigen-specific T cells. Delivering antigen to DCs via surface receptors is thus an appealing strategy to evoke cellular immunity.
Wenjie Yin, Laurent Gorvel, Sandra Zurawski, Dapeng Li, Ling Ni, Dorothée Duluc, Katherine Upchurch, JongRok Kim, Chao Gu, Richard Ouedraogo, Zhiqing Wang, Yaming Xue, HyeMee Joo, Jean-Pierre Gorvel, Gerard Zurawski, SangKon Oh   +15 more
doaj   +1 more source

Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects

Frontiers in Immunology, 2022
To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T cells (TCR T).
Paul Shafer, Paul Shafer, Paul Shafer, Lauren M. Kelly, Lauren M. Kelly, Lauren M. Kelly, Valentina Hoyos, Valentina Hoyos   +7 more
doaj   +1 more source